Dimensional Fund Advisors’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,338,995
| Closed | -$53.7M | – | 3230 |
|
|
2026
Q1 | $53.7M | Buy |
1,338,995
+1,158,070
| +640% | +$25M | 0.01% | 1460 |
|
|
2025
Q4 | $4.54M | Buy |
180,925
+162,235
| +868% | +$3.81M | ﹤0.01% | 2554 |
|
|
2025
Q3 | $423K | Buy |
+18,690
| New | +$436K | ﹤0.01% | 3020 |
|
|
2024
Q3 | – | Sell |
-33,696
| Closed | -$1.29M | – | 3354 |
|
|
2024
Q2 | $1.29M | Sell |
33,696
-34,448
| -51% | -$1.56M | ﹤0.01% | 2867 |
|
|
2024
Q1 | $4.01M | Buy |
68,144
+32,577
| +92% | +$2.08M | ﹤0.01% | 2602 |
|
|
2023
Q4 | $2.13M | Buy |
35,567
+9,500
| +36% | +$482K | ﹤0.01% | 2779 |
|
|
2023
Q3 | $992K | Sell |
26,067
-105,720
| -80% | -$4.64M | ﹤0.01% | 2930 |
|
|
2023
Q2 | $12M | Buy |
131,787
+37,801
| +40% | +$3.26M | ﹤0.01% | 2171 |
|
|
2023
Q1 | $6.2M | Buy |
93,986
+52,979
| +129% | +$3.06M | ﹤0.01% | 2413 |
|
|
2022
Q4 | $2.12K | Sell |
41,007
-41,587
| -50% | -$2.21M | ﹤0.01% | 2716 |
|
|
2022
Q3 | $5.64M | Buy |
+82,594
| New | +$4.89M | ﹤0.01% | 2385 |
|
|
2022
Q1 | – | Sell |
-9,828
| Closed | -$465K | – | 3510 |
|
|
2021
Q4 | $465K | Sell |
9,828
-574
| -6% | -$22.6K | ﹤0.01% | 3182 |
|
|
2021
Q3 | $343K | Buy |
+10,402
| New | +$584K | ﹤0.01% | 3251 |
|
Other funds holding APLS
Dimensional Fund Advisors's APLS Position: Q2 2026 in Review
Dimensional Fund Advisors sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 1,338,995 shares — an estimated $53.7M sold.
Dimensional Fund Advisors first reported a position in APLS in Q3 2021 and held it in 13 quarters. The position peaked at $53.7M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Dimensional Fund Advisors reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Dimensional Fund Advisors sold 1,338,995 Apellis Pharmaceuticals shares in Q2 2026, an estimated $53.7M.
- Dimensional Fund Advisors first reported a position in Apellis Pharmaceuticals in Q3 2021 and held it in 13 quarters.
- Dimensional Fund Advisors's Apellis Pharmaceuticals position peaked at $53.7M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.